United States - English - NLM (National Library of Medicine)

archis pharma llc - mitomycin (unii: 50sg953sk6) (mitomycin - unii:50sg953sk6) - mitomycin for injection, usp is not recommended as single-agent, primary therapy. it has been shown to be useful in the therapy of disseminated adenocarcinoma of the stomach or pancreas in proven combinations with other approved chemotherapeutic agents and as palliative treatment when other modalities have failed. mitomycin is not recommended to replace appropriate surgery and/or radiotherapy. mitomycin is contraindicated in patients who have demonstrated a hypersensitive or idiosyncratic reaction to it in the past. mitomycin is contraindicated in patients with thrombocytopenia, coagulation disorder, or an increase in bleeding tendency due to other causes.

United States - English - NLM (National Library of Medicine)

sagent pharmaceuticals - mitomycin (unii: 50sg953sk6) (mitomycin - unii:50sg953sk6) - mitomycin for injection is not recommended as single-agent, primary therapy. it has been shown to be useful in the therapy of disseminated adenocarcinoma of the stomach or pancreas in proven combinations with other approved chemotherapeutic agents and as palliative treatment when other modalities have failed. mitomycin is not recommended to replace appropriate surgery and/or radiotherapy. mitomycin is contraindicated in patients who have demonstrated a hypersensitive or idiosyncratic reaction to it in the past. mitomycin is contraindicated in patients with thrombocytopenia, coagulation disorder, or an increase in bleeding tendency due to other causes.

United States - English - NLM (National Library of Medicine)

sagent pharmaceuticals - mitomycin (unii: 50sg953sk6) (mitomycin - unii:50sg953sk6) - mitomycin for injection, usp is not recommended as single-agent, primary therapy. it has been shown to be useful in the therapy of disseminated adenocarcinoma of the stomach or pancreas in proven combinations with other approved chemotherapeutic agents and as palliative treatment when other modalities have failed. mitomycin is not recommended to replace appropriate surgery and/or radiotherapy. mitomycin is contraindicated in patients who have demonstrated a hypersensitive or idiosyncratic reaction to it in the past. mitomycin is contraindicated in patients with thrombocytopenia, coagulation disorder, or an increase in bleeding tendency due to other causes.

United States - English - NLM (National Library of Medicine)

eugia us llc - mitomycin (unii: 50sg953sk6) (mitomycin - unii:50sg953sk6) - mitomycin for injection, usp is not recommended as single-agent, primary therapy. it has been shown to be useful in the therapy of disseminated adenocarcinoma of the stomach or pancreas in proven combinations with other approved chemotherapeutic agents and as palliative treatment when other modalities have failed. mitomycin is not recommended to replace appropriate surgery and/or radiotherapy. mitomycin is contraindicated in patients who have demonstrated a hypersensitive or idiosyncratic reaction to it in the past. mitomycin is contraindicated in patients with thrombocytopenia, coagulation disorder, or an increase in bleeding tendency due to other causes.

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

takeda belgium sa-nv - mitomycin 2 mg - powder for solution for injection - 2 mg - mitomycin 2 mg - mitomycin

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

takeda belgium sa-nv - mitomycin 10 mg - powder for solution for injection - 10 mg - mitomycin 10 mg - mitomycin

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

takeda belgium sa-nv - mitomycin 20 mg - powder for intravesical solution - 20 mg - mitomycin 20 mg - mitomycin

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

accord-uk ltd - mitomycin - powder for solution for injection - 2mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

accord-uk ltd - mitomycin - powder for solution for injection - 10mg

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - mitomycin 10mg - powder for injection - 10 mg - active: mitomycin 10mg excipient: mannitol - mitomycin is used in palliative tumour therapy. mitomycin is administered intravenously as monochemotherapy or in combined cytostatic chemotherapy in the case of: · advanced metastatic gastric carcinoma · advanced and/or metastatic breast cancer furthermore mitomycin is administered intravenously in combined chemotherapy in the case of: · non-small cell bronchial carcinoma · advanced pancreatic carcinoma intravesical administration for relapse prevention in superficial urinary bladder carcinoma after transurethral resection.